Compare Cytokinetics Inc (CYTK) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Roundhill Magnificent Seven ETF — how do they compare? Cytokinetics Inc trades at $62.75 (market cap $8.62B), while Roundhill Magnificent Seven ETF trades at $73.72 (market cap $5.78B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| CYTK | MAGS | |
|---|---|---|
Market Cap | $8.62B | $5.78B |
Volume | 2,594,626 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $87.26 | $73.90 |
52-Week Low | $54.76 | $55.39 |
Typical Hold Time | 19 Days | 36 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.63, down slightly by 0.08% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights ongoing investor debate about the Magnificent Seven's leadership role amid shifting AI investment trends.
The ETF faces near-term pressure from underperformance versus the S&P 500 but maintains long-term growth potential through diversified tech exposure. Key risks include concentration in seven stocks and market rotation away from mega-caps, while the bullish technical setup suggests potential for near-term recovery if AI momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
